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Urinary tract infections (UTIs) are associated with high rates of morbidity and mortality
worldwide, and uropathogenic Escherichia coli (UPEC) is the main etiologic agent.
Fimbriae assembled on the bacterial surface are essential for adhesion to the urinary tract
epithelium. In this study, the FimH, CsgA, and PapG adhesins were fused to generate
biomolecules for use as potential target vaccines against UTIs. The fusion protein design
was generated using bioinformatics tools, and template fusion gene sequences were
synthesized by GenScript in the following order fimH-csgA-papG-fimH-csgA (fcpfc)
linked to the nucleotide sequence encoding the [EAAAK]5 peptide. Monomeric (fimH,
csgA, and papG), dimeric (fimH-csgA), and trimeric (fimH-csgA-papG) genes were
cloned into the pLATE31 expression vector and generated products of 1040, 539, 1139,
1442, and 2444 bp, respectively. Fusion protein expression in BL21 E. coli was induced
with 1mM IPTG, and His-tagged proteins were purified under denaturing conditions and
refolded by dialysis using C-buffer. Coomassie blue-stained SDS-PAGE gels andWestern
blot analysis revealed bands of 29.5, 11.9, 33.9, 44.9, and 82.1 kDa, corresponding to
FimH, CsgA, PapG, FC, and FCP proteins, respectively. Mass spectrometry analysis by
MALDI-TOF/TOF revealed specific peptides that confirmed the fusion protein structures.
Dynamic light scattering analysis revealed the polydispersed state of the fusion proteins.
FimH, CsgA, and PapG stimulated the release of 372–398 pg/mL IL-6; interestingly,
FC and FCP stimulated the release of 464.79 pg/mL (p ≤ 0.018) and 521.24 pg/mL
(p ≤ 0.002) IL-6, respectively. In addition, FC and FCP stimulated the release of
398.52 pg/mL (p ≤ 0.001) and 450.40 pg/mL (p ≤ 0.002) IL-8, respectively. High levels
of IgA and IgG antibodies in human sera reacted against the fusion proteins, and under
identical conditions, low levels of IgA and IgG antibodies were detected in human urine.
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Rabbit polyclonal antibodies generated against FimH, CsgA, PapG, FC, and FCP blocked
the adhesion of E. coli strain CFT073 to HTB5 bladder cells. In conclusion, the FC
and FCP proteins were highly stable, demonstrated antigenic properties, and induced
cytokine release (IL-6 and IL-8); furthermore, antibodies generated against these proteins
showed protection against bacterial adhesion.
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INTRODUCTION
Urinary tract infections (UTIs) are associated with high rates
of morbidity and mortality worldwide (Foxman, 2010; Flores-
Mireles et al., 2015; Kumar et al., 2015). In Mexico, UTIs are
a public health problem and are the third leading cause of
morbidity, with ∼4 million cases per year (Secretaria de Salud,
2009). Populations with a high risk of acquiring UTIs include
newborns, preschool girls, women who are sexually active, and
both sexes at advanced ages (Foxman, 2002, 2014).
Uropathogenic Escherichia coli (UPEC) is the primary
etiologic agent responsible for UTIs, which are classified
according to the site of infection: urine (asymptomatic
bacteriuria), bladder (cystitis), kidney (pyelonephritis), and
blood (urosepsis and bacteremia; Foxman, 2002). The pathogenic
mechanism of UPEC begins with adherence via fimbrial adhesins
(FimH, PapG, SfaS, and FocH), which are assembled on the
distal tip of type 1, P, S, and F1C fimbriae, respectively.
Additionally, CsgA (Curli fimbriae) and DrA (Dr fimbriae)
proteins have been implicated in epithelial cell adhesion (Antão
et al., 2009). These adhesins interact with different receptors (α-
D-mannosylated proteins, glycosphingolipids, neuraminic acid,
lactosylceramide, decay accelerating factor, and matrix proteins)
located on the membrane of cells of the urinary tract (Antão
et al., 2009; Lüthje and Brauner, 2014). The FimH adhesin
of type 1 fimbriae interacts with uroplakin proteins in the
bladder, resulting in an invasion process that allows UPEC
to avoid urine flow, antibodies, bactericidal molecules, and
antibiotic activity in the urinary tract (Mulvey et al., 1998, 2000;
Zhou et al., 2001). UPEC produces biofilm-like structures called
intracellular-bacterial communities (IBCs) within the cytoplasm
of urothelial cells, conferring protection to the bacteria and
facilitating their egress to promote a new cycle of infection
through bladder cell lysis (Scott et al., 2015). During infection
cycles, UPEC enter a quiescent state for long periods of time,
and this quiescence constitutes a mechanism for bacterial
persistence (Leatham-Jensen et al., 2016). UPEC then exit the
quiescent state by promoting exocytosis from bladder cells
and infecting new cells, resulting in recurrent UTIs (rUTIs,
Leatham-Jensen et al., 2016). Three percent of women with
three or more rUTIs annually are at risk for developing
pyelonephritis and urosepsis (Foxman, 2002, 2010). UTIs
are typically treated with several broad-spectrum antibiotics
(ampicillin, trimethoprim/sulfamethoxazole, fluoroquinolones,
and cephalosporin), resulting in increased resistance rates among
clinical UPEC strains. This resistance complicates treatment,
increases costs, and decreases the efficiency of antibiotics
against infection (Biedenbach et al., 2016). The indiscriminate
use of antibiotics modifies the commensal microbiota of
patients and generates secondary infections (candida-vaginal
and gastrointestinal infections) during and after prophylactic
treatment (Flores-Mireles et al., 2015).
The FimH adhesin of UPEC type 1 fimbriae has been
used as a biomolecule to induce protection in murine models
(Langermann et al., 1997, 2000; Langermann and Ballou, 2001).
During infection, type 1 fimbrial expression is regulated by
environmental conditions (temperature, osmolality, pH, and
nutrients) as well as the specific anatomic site of infection in
the urinary tract (bladder, ureters, and kidney). These conditions
also dictate the expression of other fimbriae that promote urinary
tract colonization by UPEC (Snyder et al., 2005; Greene et al.,
2015).
P fimbriae of UPEC have been associated with colonization
and inflammation in the kidneys (pyelonephritis) through
binding of PapG adhesion to Gal(α1-4)Gal-containing
glycolipids and Toll-like receptor (TLR) 4 in kidney cells
(Frendéus et al., 2001; Lane and Mobley, 2007). Curli fimbriae
are primarily composed of CsgA protein monomers and
are associated with cystitis, pyelonephritis, and bacteremia
(Norinder et al., 2012; Hung et al., 2014; Lim et al., 2014). These
fimbriae are widely distributed in clinical strains of UPEC and
are finely regulated by a regulatory system of on-to-off and/or
off-to-on switching (Snyder et al., 2005). Recombinant proteins
generated using fusion technology to contain one or more
antigens derived from diverse pathogens can induce immune
and protective responses against UTIs in in vivo models (Asadi
Karam et al., 2013; Habibi et al., 2015b). Vaccines designed
based on fused proteins of UPEC clinical strains with high
variability in their virulence factors might represent potential
tools for preventing UTIs. The aim of this study was to generate
recombinant fusion proteins (combination of FimH, PapG, and
CsgA proteins) as viable biomolecules with vaccine properties to
significantly reduce UTIs in Mexico.
MATERIALS AND METHODS
Primary, Secondary, and Tertiary
Structures
FimH, CsgA, and PapG protein sequences from the E. coli
strain CFT073 were obtained from the NCBI database (http://
www.ncbi.nlm.nih.gov/protein) under accession numbers
AAN83822.1, AAN79779.1, and AAN82031.1, respectively.
Signal peptide prediction was performed for each protein using
the SignalP 4.1 server, and five repetitions of the EAAAK
sequence were employed to fuse the FimH, CsgA, and PapG
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proteins based on the linker library construction proposed by Li
et al. (2016).
In addition, the molecular weight, theoretical isoelectric point
(pI), amino acid composition, estimated lifetime, aliphatic index,
and grand average of hydropathicity (GRAVY) of the fusion
proteins were determined using the ProtParam program of
ExPASy (Wilkins et al., 1999). The Codon Adaptation Index
(CAI) and guanine and cytosine (GC) content of the genes
were determined using the OPTIMIZER program (Puigbò et al.,
2007). The secondary structure of the fusion proteins was
predicted using the GOR IV program (Sen et al., 2005). Fusion
protein modeling was performed using the hierarchical modeling
approach (I-TASSER) and visualized with PyMOL software (Yang
et al., 2015). Tridimensional (3D) structures were refined and
minimized with KoBaMIN (http://csb.stanford.edu/kobamin/)
and VegaZZ (NAMD; Pedretti et al., 2004). The 3D models
were then validated by Protein Structure Analysis (ProSA) to
determine Z-scores and Ramachandran plots using PROCHECK
(Laskowski et al., 1998; Wiederstein and Sippl, 2007). Merging of
the 3D fusion proteins with the crystal structures of themannose-
binding domain FimH (Protein Data Bank; 1TR7) and lectin
domain PapG (PDB; 1J8R) were calculated with the root mean
square deviation (RMSD) using the TM-align program (Zhang
and Skolnick, 2005).
Epitope Prediction and Antigen
Presentation
Immune response was theoretically determined to establish
variants of fusion proteins with enhanced ability to generate
an immune response. The primary and secondary structures
of the fusion proteins were employed to determine the lineal
antigenic epitopes of B with the AbcPred server (http://
www.imtech.res.in/raghava/abcpred/), and peptides with
affinities for major histocompatibility complex (MHC) class
II were identified with the NetMHCII program (http://
www.cbs.dtu.dk/services/NetMHCII/). The 3D structures
of the fusion proteins were employed to determine the
conformational antigenic epitopes using the Discotope server
(http://www.cbs.dtu.dk/services/DiscoTope/).
Analysis and Synthesis of a Template
Fusion Gene
The gene sequences of fimH, csgA, and papG from the E. coli
strain CFT073 were obtained from GenBank through NCBI
(http://www.ncbi.nlm.nih.gov/genbank/) under the accession
numbers GQ487191.1, NC_004431.1, and AF447814.1,
respectively. The conserved sequences of the fimH, csgA,
and papG genes from various UPEC strains (UTI89, ABU83972,
NA114, UPEC 26-1, CF-088, CF-468, isolates IA2, and AD110)
were determined using the BLAST (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) and Clustal Omega (http://www.ebi.ac.uk/Tools/
msa/clustalo/) programs. Consensus nucleotide sequences were
fused with the appropriate codons from the sequence EAAAK to
generate a template fusion gene. The sequence of the template
fusion gene was optimized using the OPTIMIZER program
(http://genomes.urv.es/OPTIMIZER/), and messenger RNA
secondary structures of monomeric, dimeric, and trimeric genes
were predicted using the Mfold program (http://unafold.rna.
albany.edu/?q=mfold/RNA-Folding-Form). The optimized
template fusion gene, containing a 5′ BamHI site and 3′ SacI site,
was synthesized by GenScript (Piscataway, NJ, USA) and cloned
into the pUC57 vector to amplify and clone monomeric, dimeric,
and trimeric genes.
Cloning of Monomeric and Fusion Genes
into the pLATE Expression Vector
Primer designs for monomeric, dimeric, and trimeric genes from
the synthetized template fusion gene were generated manually
according to the aLICator LIC Cloning and Expression handbook
(Thermo Fisher Scientific, Waltham, MA, USA) and synthesized
by IDT Technologies (Coralville, Iowa, USA). Gene amplification
was performed by polymerase chain reaction (PCR) using Pfu
DNA polymerase. Conditions for amplification and cloning
were obtained from the aLICator LIC Cloning and Expression
handbook. The pLATE31 expression vector was used to clone
the fusion genes and transformed by electroporation into BL21
(DE3) E. coli.
Sequencing and GenBank Submission of
the Fusion Genes
Fusion genes in recombinant vectors were verified by next-
generation sequencing on a NexSeq 500 system (Illumina, San
Diego, CA, USA). Specific sequencing primers were obtained
from the aLICator LIC Cloning and Expression Kit, and the gene
sequences were analyzed by BLAST and submitted to GenBank
at NCBI.
Expression and Purification of Fusion
Proteins
A BL21 E. coli strain carrying the pLATE31 expression
vector (fusion proteins) was plated on Luria Bertani (LB;
Becton-Dickinson, Franklin Lakes, New Jersey, USA) agar and
incubated for 16 h at 30◦C. The putative transformant colonies
were selected via the colony-blotting method using an anti-
6X His (C-Term) HRP antibody (Abcam; Cambridge, MA,
USA). Solubility assays were performed following the protocol
described in the QIAexpressionist manual fromQiagen (Jacques-
Schiesser-Str, Stockach, Germany). Fusion protein expression
was performed in 500mL of LB medium supplemented with 1
mM IPTG for 5 h at 37◦C. The cell pellets were resuspended
in phosphate buffer (10 mM K2HPO4, pH 7.4, 150 mM NaCl,
and 1mM EDTA) with phenylmethylsulfonyl fluoride (PMSF;
Sigma-Aldrich Corp., St. Louis, MO, USA), lysed by sonication,
and centrifuged at 26,116 g for 20 min. The supernatants were
discarded, and the pellets were resuspended in denaturing buffer
(8M guanidine, 100mM NaCl, and 100mM K2HPO4, pH 8).
After 3 days of incubation at room temperature, the lysates
were centrifuged at 58,762 g for 20 min. The supernatants were
incubated on a column containing nickel-nitrilotriacetic acid-
agarose (Qiagen) at 4◦C for 1 h, washed with A-buffer (8.5M
urea, 20mM Tris, pH 7.5, 160mM NaCl, and 20mM imidazole)
and eluted with B-buffer (8M urea, 50mM Na2HPO4, pH 8,
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100mM NaCl, and 500 mM imidazole). The collected proteins
underwent refolding via dialysis using a urea gradient from 7
to 1 M in C-buffer (25 mM Tris, pH 7.5, 100mM NaCl, and
0.5 mM EDTA); incubation was performed at 4◦C for 24 h.
Refolded fusion proteins were stored in C-buffer at−70◦C for all
assays.
Characterization of Fusion Proteins
Fusion proteins were quantified according to the protocol
for the 2D-Quant kit (GE Healthcare Bio-Sciences AB,
Björkgatan, Uppsala, Sweden), separated by performing 14%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), visualized by Coomassie staining and identified by
mass spectroscopy using a 4800 MALDI TOF/TOF
TM
Analyzer
(Applied Biosystems/MDS SCIEX, Waltham, MA, USA) after
excision of the proteins spots. The CsgA protein was treated
with 88% formic acid (Sigma-Aldrich Corp., St. Louis, MO, USA)
prior to SDS-PAGE (Saldaña et al., 2009). Molecular weights
were estimated using Image Lab software version 5.2 from
Bio-Rad (Hercules, California, USA). The aggregation state of
fusion proteins was determined by performing dynamic light
scattering (DLS) using a Zetasizer Helix (Malvern Instruments
Ltd, Grovewood Road, Worcestershire, United Kingdom).
Fusion proteins with histidine tags were transferred onto
polyvinylidene difluoride (PVDF) membranes and confirmed by
performing Western blot assays using anti-6His (C-Terminal)
HRP antibodies (Abcam; Cambridge, MA, USA) as described
by Ledesma et al. (2010). The endotoxin (LPS) levels of the
purified fusion proteins were determined using the Pierce
TM
LAL Chromogenic Endotoxin Quantitation kit according to the
manufacturer’s protocol (Thermo Fisher Scientific; Waltham,
MA, USA). Additionally, fusion proteins were treated with
50µg/mL polymyxin B (Sigma-Aldrich Corp., St. Louis, MO,
USA) for 12 h at 4◦C prior to bioactivity assays.
Bioactivity Assays Using the Fusion
Proteins
TLR2 and TLR4 expression in HTB5 bladder cells [American
Type Culture Collection (ATCC), Manassas, VA, USA] was
analyzed by flow cytometry using a human TLR2 fluorescein-
conjugated antibody (R&D Systems, Inc., Minneapolis, USA)
and a human TLR4/MD-2 complex phycoerythrin-conjugated
antibody (Santa Cruz Biotechnology Inc., Texas, USA).
Activation of TLR2 and TLR4 by the fusion proteins was assessed
by quantifying the release of IL-6 and IL-8. HTB5 cells were
cultured in 24 well-plates (Greiner, Germany) at a density of
105 cells/well incubated with 1 mL of fresh Eagle’s minimum
essential medium (EMEM; ATCC R© 30-2003TM) supplemented
with 10% fetal bovine serum (FBS) from Gibco (Thermo
Fisher Scientific; Waltham, MA, USA). Cytokine induction in
HTB5 cells was detected after 6 h of incubation with 10µg/mL
FimH, CsgA, PapG, FC, and FCP proteins by performing
enzyme-linked immunosorbent assays (ELISAs) following the
protocol established by BD Biosciences (San Jose, CA, USA).
In addition, 100 ng/mL lipopolysaccharide (LPS; Sigma-Aldrich
Corp., St. Louis, MO, USA) from E. coli 0111:B4 and 100 ng/mL
lipoteichoic acid (LTA; Sigma-Aldrich Corp., St. Louis, MO,
USA) from S. aureus were used as controls for the induction of
TLR4 and TLR2, respectively.
Antigenicity of Fusion Proteins
The study was approved by the Research (Dr. Onofre
Muñoz Hernández), Ethics (Dr. Amparo Faure Fontenla), and
Biosecurity (Dr. Herlinda Vera Hermosillo) Committees of
Hospital Infantil de México Federico Gómez (HIMFG) under
numbers HIM/2014/022 and HIM/2016/027. Physicians from
the Infectology Department obtained permission and consent
from patients to use the urine and serum samples employed
in this study. Serum and urine samples were collected from
14 UTI patients (UP); samples from 14 healthy patients (HP)
recruited from “Laboratorio Central del HIMFG” were used as
negative controls. Patients were selected based on the following
criteria: UTI symptoms, urine culture with ≥100,000 CFU/mL
E. coli, leukocyte esterase and/or nitrites, and urothelial cells
in urine. Urine samples were centrifuged at 7835 g for 5min
and filtered through a 0.22-µm Durapore membrane (Merck
Millipore; Darmstadt, Germany). IgG and IgA antibody titers
against the FimH, CsgA, PapG, FC, and FCP proteins were
determined by ELISA using serum and urine samples diluted 1:50
and 1:10, respectively.
Generation of Polyclonal Rabbit Antibodies
Five female 6-month-old New Zealand rabbits were obtained
from the “Instituto de Fisiología Celular de la Universidad
Nacional Autónoma de México” for use in this study. Initially,
the rabbits were immunized subcutaneously with 200µg of
FimH, CsgA, PapG, FC, and FCP proteins in complete Freund’s
adjuvant. The rabbits were re-immunized three times (days
21, 28, and 37) with 100µg of each protein in incomplete
Freund’s adjuvant and bled via cardiac puncture on day 40. The
collected blood was centrifuged at 7835 g for 5min, and separated
sera were stored at −70◦C until use. The sera were absorbed
using the CFT073 csgA::km + fimH::cm mutant strain generated
in this study via a one-step inactivation method (Datsenko
and Wanner, 2000). Anti-PapG and anti-FCP polyclonal rabbit
sera were adsorbed using the CFT073 csgA::km + fimH::cm
mutant strain under conditions that did not permit PapG
expression, as confirmed by RT-PCR. Additionally, sera were
heat-inactivated at 56◦C for 30min and titrated by ELISA using
serial dilutions from 1:10 to 1:100,000 against the appropriate
proteins.
Adherence Inhibition Assay with HTB5
Bladder Cells
HTB5 bladder cells were cultured in 24 well-plates at a density
of 105 cells/well in 1 mL of fresh EMEM supplemented with
10% FBS until 80% confluence was reached. Previously, the
strain CFT073 was grown overnight in LB broth at 37◦C,
and an aliquot (1:100 dilution) of the culture was incubated
until it reached an OD600 of 1.0. The bacterial culture was
then mixed with pre-immune or/and immune serum at a 1:1
ratio and maintained 2 h at 37◦C with constant agitation. Cell
monolayers were infected with 107 bacterial cells [multiplicity
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of infection (MOI): 100] and incubated for 2 h at 37◦C in
5% CO2. Infected cell monolayers were washed three times
with PBS, and 200µL of PBS containing 0.1% Triton X-100
was added. The bacteria that adhered to the cell monolayers
were homogenized, and colony-forming units were determined
using the Spotting Method described by Hannan and Hunstad
(2016).
Statistical Analysis
One-way ANOVA and Student’s t-test were used to compare
differences between the mean and median values of groups using
GraphPad Prism software (version 6). A p< 0.05 was considered
statistically significant for all results.
RESULTS
Structural Components of the Fusion
Proteins
Fusion proteins were generated using the sequences of the fimH,
papG, and csgA genes, which exhibit identity of ≥90% among
clinical UPEC strains. In addition, a signal peptide was identified
between residues 1 and 27 of the sequences of the FimH and PapG
proteins and residues 1–21 of the CsgA protein. Additionally,
the CsgA protein contained a nucleation region between residues
22 and 41. These signal peptides and the nucleation region were
eliminated from the sequences used to design and synthesize of
the fusion proteins. The fusion of the FimH, PapG, and CsgA
proteins was generated by employing the five repeats of the
EAAAK linker ([EAAAK]5), which forms an alpha helix with a
length of 39.95 A˙ stabilized by five salt bridges between the Glu−
and Lys+ residues.
Generation of Dimeric and Trimeric Genes
A template fusion gene containing (in order) fimH-csgA-
papG-fimH-csgA (fcpfc) linked to the nucleotide sequence of
the [EAAAK]5 peptide was designed (Figure 1A). Six specific
primers localized in the 5′ (forward) and 3′ (reverse) regions
of each gene were designed and synthesized as described in
the aLICator LIC Cloning and Expression Handbook (Table 1).
Monomeric, dimeric, and trimeric genes were generated using
combinations of the six primers in PCR amplification and cloned
into the pLATE31 expression plasmid (Figure 1B).
Synthesis of the Template Fusion Gene
Increased expression levels of the fusion genes were obtained by
preferential codon optimization of the fcpfc template fusion gene,
which exhibited a CAI of 0.433–1.0 and a GC content of 48.9–
55.4%. The fcpfc-optimized gene was synthesized chemically and
cloned into the pUC57 vector to produce pF2C2P. Sequencing
and digestion of the pF2C2P were consistent with the theoretical
profile (data not shown).
Primary and Secondary Structures
The physical and chemical parameters of the monomeric (FimH,
CsgA, and PapG), dimeric [FimH-CsgA (FC), CsgA-PapG
(CP), and PapG-FimH (PF)], and trimeric [FimH-PapG-CsgA
(FCP), PapG-CsgA-FimH (PCF), and CsgA-FimH-PapG (CFP)]
proteins are shown in Table 2. Primary sequence analysis of these
proteins revealed a high number of linear epitopes, between
18 and 33, as well as a high number of peptides binding to
MHC-II, between 68 and 159 (Table 3). The secondary structure
predictions for the monomeric, dimeric, and trimeric proteins
indicated a high percentage of random coil and beta-sheet
FIGURE 1 | Cloning strategy for the fusion proteins. (A) The template gene sequence was constructed with the following order: fimH-csgA-papG-fimH-csgA
linked with a GAAGCGGC GGCGAAA sequence repeated five times. (B) Generation of the fusion genes from the combination of specific primers for each gene.
Dimeric and trimeric genes are abbreviated with the first letter of the fimH (f ), csgA (c), and papG (p) genes.
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TABLE 1 | List of primers used in this study.
Number Primer Sequence (5′-3′) References
1 FimH F AGAAGGAGATATAACTATGAAAACCGCGAACGGTACCGCGATCCCGATCGGTGGTGGT This study
2 FimH R GTGGTGGTGATGGTGATGGCCCTGGTAAACGAAGGTAACACCGATGATAGACTGAAC This study
3 CsgA F AGAAGGAGATATAACTATGTCTGAACTGAACATCTACCAGTACGGTGGTGGTA This study
4 CsgA R GTGGTGGTGATGGTGATGGCCGTACTGGTGCGCGGTCGCGTTGTTACCGAA This study
5 PapG F AGAAGGAGATATAACTATGTCTCTGGGTAACGTTAACTCTTACCAGGGTGGTAA This study
6 PapG R GTGGTGGTGATGGTGATGGCCCGGCAGGATCATCAGCAGGGTCGCAGAACCAG This study
TABLE 2 | Analysis of the physiochemical parameters of the fusion proteins.
Protein No. of amino acids Molecular weight (kDa) Theoretical pI Extinction coefficient Estimated half-life Instability index Aliphatic index GRAVY
FimH 283 29.64 6.63 1.179 10 25.59 85.72 0.029
CsgA 116 12.06 5.58 0.826 10 16.23 51.38 −0.791
PapG 316 35.38 8.89 1.882 10 25.89 74.05 −0.364
FC 417 43.09 5.66 1.043 10 21.74 76.07 −0.183
CP 450 48.83 6.92 1.563 10 21.37 68.58 −0.443
PF 617 66.4 8.44 1.529 10 25.58 79.68 −0.161
FCP 751 79.85 6.74 1.397 10 22.37 75.39 −0.245
CPF 751 79.85 6.74 1.397 10 22.37 75.39 −0.245
PFC 751 79.85 6.74 1.397 10 22.37 75.39 −0.245
TABLE 3 | B-cell epitopes and MHC class II binding peptide predictions for
the fusion proteins.
Fusion Lineal Conformational MHC class II
protein epitopes epitopes binding peptide
FC 18 13 86
CP 27 12 68
PF 32 8 147
FCP 32 17 149
CPF 33 14 152
PFC 33 13 159
structures; however, lower percentages of alpha helices were
observed (Figure 2). The conserved region of the alpha helix
structure conferred by the [EAAAK]5 linker was identified in all
fusion proteins.
3D Structures of the Fusion Proteins
The 3D structure models of the dimeric and trimeric proteins
were refined 10 times to obtained the optimal minimization
energy (Figure 2 and Table 4). Interestingly, the FC and
FCP proteins exhibited models with optimal theoretical data
that indicated a stable structural conformation. Gibbs free
energy (1G) data indicated high stability for the FC protein,
with 1G = −7040.78 kcal/mol, and the FCP protein, with
1G = −13,343.83 kcal/mol (Table 4). The 3D model validation
of the FC and FCP proteins indicated that 94.7 and 93.1% of
the amino acid residues were within permitted regions in the
Ramachandran plot, with Z-scores of −6.95 (FC) and −9.53
(FCP).
The 3D models of the FC and FCP proteins exhibited RMSDs
of 1.81 and 1.67 Å, respectively, indicating conformations very
similar to that of the mannose-binding domain of FimH. The
FCP protein also exhibited an RMSD of 1.62 Å with the lectin
domain of PapG (Table 4). Analysis of the 3D models using the
Discotope program revealed 13 and 17 conformational epitopes
in the FC and FCP proteins, respectively (Table 3).
Generation of Fusion Proteins
Bioinformatic analysis was an essential tool for the selection of
monomeric (fimH, csgA, and papG), dimeric (fc), and trimeric
(fcp) genes, which were cloned in the pLATE31 expression vector.
PCR assays were performed to verify the cloned expression
vectors using specific sequencing primers as described in the
aLICator LIC Cloning and Expression Handbook (Figure 3A).
The sequences of the fusion genes were determined by
sequencing and will be submitted to the GenBank database
(unpublished data). The BL21 (DE3) E. coli strain carrying the
expression vectors was induced with 1 mM IPTG, and the His-
tagged fusion proteins were purified under denaturing conditions
by affinity chromatography. Coomassie blue-stained SDS-PAGE
gels and Western blot analysis revealed 26.5, 11.9, 33.9, 44.9, and
82.1 kDa bands corresponding to FimH, CsgA, PapG, FC, and
FCP, respectively (Figures 3B,C). The protein concentrations of
FimH, CsgA, PapG, FC, and FCP were 2.7, 0.697, 2.63, 1.03, 0.998
mg/mL, respectively.
Mass spectrometry analysis by MALDI-TOF/TOF revealed
the presence of specific peptides corresponding to the fusion
proteins, and DLS analysis of the fusion proteins indicated a
polydispersed state (Table 5).
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FIGURE 2 | Prediction of the secondary and tertiary structures of the fusion proteins. (A) FC protein. (B) CP protein. (C) PF protein. (D) FCP protein. (E) CPF
protein. (F) PFC protein. Dimeric and trimeric proteins were abbreviated (color) as follows: FimH (blue), CsgA (red), and PapG (green) proteins. Underlined and bold
sequences correspond to the EAAAK linker (gray). Secondary structure prediction: (purple) extended strand, (red) coil, and (blue) helix.
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TABLE 4 | Parameters for 3D modeling, refinement, and validation of the fusion proteins.
Fusion protein Refinement cycle Minimization energy (1G) (kcal/mol) Ramachandran plot (%) Z-score RMSD (FimH-PapG)
FC 10 −11,912.82 94.70 −6.97 1.81 A˙−NA
CP 10 −7040.78 92.30 −7.7 NA−2.02 A˙
PF 10 −7140.54 92.40 −7.7 1.83 A˙−1.37 A˙
FCP 10 −13,866.68 93.10 −9.53 1.67 A˙−1.62 A˙
CPF 10 −13,343.83 92.50 −10.72 1.99 A˙−2.02 A˙
PFC 10 −13,577.65 91.90 −10.68 1.88 A˙−1.38 A˙
Calculations for RMSD were generated with the FimH-lectin domain (PDB 1TR7) and PapG-lectin domain (PDB 1J8R). NA, not applicable.
FIGURE 3 | Generation of the fusion proteins. (A) The specific primers were combined to amplify the fusion genes by PCR, cloned in the pLATE31 plasmid and
verified by colony PCR. (B) Fusion genes cloned into pLATE31 were used to transform BL21 (DE3) E. coli, followed by induction with 1mM IPTG and purification of
the 6His-tagged fusion proteins by Ni-NTA affinity chromatography. (C) Western blot assays with anti-6His (C-Term) HRP antibodies were employed to verify the
fusion. Line 1 corresponds to FimH (1040 bp and 29.5 kDa), line 2 to CsgA (539bp and 11.9 kDa), line 3 to PapG (1139 bp and 33.9 kDa), line 4 to FC (1442 bp and
44.9 kDa), and line 5 to FCP (2444bp and 82.1 kDa). MW, molecular weight. bp, base pairs.
Induction of Proinflammatory Cytokine
Release by the Fusion Proteins
Flow cytometry analysis of HTB5 bladder cells revealed an
expression of 50.3% for TLR2 and 31.7% for TLR4 (Figure 4).
Endotoxin levels ≤ 0.012 EU/mL were observed when the
FimH, CsgA, PapG, FC, and FCP proteins were treated with
50µg/mL polymyxin B. HTB5 bladder cells expressing TLR2 and
TLR4 were incubated with 10µg/mL FimH, CsgA, PapG, FC,
or FCP, which induced different percentages of IL-6 and IL-8
cytokine release. Briefly, the FimH, CsgA, and PapG proteins
stimulated the release of 372–398 pg/mL IL-6, and no significant
differences in IL-6 release were observed among these proteins.
However, the FC and FCP proteins induced the release of 464.79
and 521.24 pg/mL IL-6, respectively, which were significantly
different (p ≤ 0.018 and p ≤ 0.002, respectively) from the values
obtained for the monomeric proteins (Figure 5). In addition,
398.52 pg/mL IL-8 was released by the FC protein (p ≤ 0.003
compared to the monomeric protein), and 450.40 pg/mL IL-8
was released by the FCP protein (p ≤ 0.037 compared to the
monomeric protein; Figure 6).
Antigenicity of the Fusion Proteins
ELISA assays were performed to detect antibodies against the
FimH, CsgA, PapG, FC, and FCP proteins in the sera and urine
of HP and UP (Figures 7, 8). Antibodies in the sera reacted
with all proteins evaluated. High levels of UP-IgA antibodies
in sera were observed, with a median OD450 of 1.628–2.216.
Interestingly, high levels of UP-IgA antibodies in sera, with
a median OD450 of 2.216 were detected when ELISA was
performed using the FC protein as an antigen (Figure 7B).
However, under identical conditions, low levels of UP-IgG
(median values of 0.514–0.837) were detected. The FC protein
exhibited greater specificity, with sera detecting UP-IgG with
a median value of 0.837 (Figure 7A). Additionally, all fusion
proteins reacted with high levels of UP-IgA antibodies in urine,
with a significant difference of p = 0.0003 compared to the
values for HP-IgA antibodies. Furthermore, 1µg/mL fusion
protein detected high levels of UP-IgA antibodies in urine, with
median values ranging from 0.6189 to 0.950 (Figure 8B). In
contrast, low levels of UP-IgG were detected in urine, with
median values ranging from 0.444 to 0.619 (Figure 8A). The
difference in the values between UP-IgA and UP-IgG in urine
was significant (p < 0.05) compared to HP-IgA and HP-IgG
(Figure 8).
Polyclonal Rabbit Antibodies Block
Bacterial Adherence
Polyclonal rabbit antibodies against the FimH, CsgA, PapG, FC,
and FCP proteins were used to block bacterial adherence to
HTB5 bladder cells. The strain CFT073 showed adherence to
6.3× 106 HTB5 bladder cells, and this level of adherence was set
at 100%. Similar adherence by the strain CFT073 was observed
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FIGURE 4 | Expression of TLR2 and TLR4 in HTB5 bladder cells. Expression of TLR2 and TLR4 in HTB5 bladder cells was analyzed by flow cytometry. (A)
Unstained HBT5 cells. (B) HTB5 cells incubated with an isotype control. (C) TLR2 expression in HTB5 cells analyzed using human TLR2 fluorescein-conjugated
antibodies. (D) TLR4 expression in HTB5 cells analyzed using human TLR4/MD-2 complex phycoerythrin-conjugated antibodies.
with pooled pre-immune sera (Figure 9). Bacterial adherence in
the presence of polyclonal rabbit antibodies showed a significant
reduction to 32% for anti-FimH (p = 0.002), 21% for anti-CsgA
(p = 0.0011), 60% for anti-PapG (p < 0.0001), 73% for anti-FC
(p < 0.0001), and 46% for anti-FCP (p < 0.0001) compared with
the CFT073 and pre-immune serum controls (Figure 9).
DISCUSSION
UTIs are the second most common infection in humans and
are associated with high annual economic costs due to patient
morbidity. UPEC is the most common etiologic agent of UTIs
(Foxman, 2014). Increased antibiotic resistance among UPEC
strains has reduced treatment options and significantly increased
UTI-associated morbidity and mortality (Melzer and Petersen,
2007; Molina-López et al., 2011). Research to date has focused
on more effective and less costly options for antibiotic therapy
to treat UTIs and vaccination as a viable alternative due to
increasing resistance among UPEC strains (Serino et al., 2010;
Sivick and Mobley, 2010; Brumbaugh and Mobley, 2012; Moriel
and Schembri, 2013; Mobley and Alteri, 2015).
Fusion technology has been utilized to design new vaccines
due to its ability to induce a rapid cellular and humoral
immunity response against UPEC (Huleatt et al., 2007). Fimbrial
adhesin plays a critical role in UPEC binding, colonization,
and bladder and kidney cell invasion (Spaulding and Hultgren,
2016). We hypothesized that blocking adhesion using anti-
fimbrial adhesin antibodies would inhibit the initial step in
the UPEC pathogenic mechanism. Fusion proteins comprising
the FimH, PapG, and CsgA adhesins and EAAAK rigid linkers
were designed and analyzed using bioinformatics tools. Based
on bioinformatics, we selected the [EAAAK]5 peptide, which
contains a longer helix that results in appropriate separation
among fusion proteins. Small-angle X-ray scattering data have
revealed that multimerization is caused by short helical linkers
(n = 2–3), whereas longer linkers (n = 4–5) solvate monomeric
fusion proteins (Arai et al., 2004; Zagrovic et al., 2005). The
monomeric, dimeric, and trimeric fusion genes generated from
the fcpfc optimized-template exhibited a CAI value of 1.0 and a
high GC content (55.4%). Thus, the designed sequence appears
to be optimal for expressing all fusion proteins, as described
in previous studies (Brinkmann et al., 1989; Andrews et al.,
1996; Pedersen-Lane et al., 1997). Three different variants of the
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FIGURE 5 | Fusion proteins activate IL-6 release. HTB5 cells were treated
with 10µg/mL of each fusion protein, and IL-6 release into the supernatant
was detected by ELISA. Maximal induction of IL-6 was generated by the FCP
protein, which exhibited significant (p ≤ 0.002) differences compared to the
FC, FimH, CsgA, and PapG proteins. The FC protein also produced a
significant increase (p ≤ 0.018) in IL-6 release compared to the FimH, CsgA,
and PapG proteins. The bars represent the mean ± S.D. of three independent
experiments. LPS and LTA (100 ng/mL) were used as controls.
dimeric (fc, cp, and pf ) and trimeric (fcp, cpf, and pfc) genes
were designed to construct and express the fusion proteins.
However, based on theoretical analysis of the fusion proteins, FC,
and FCP were selected for their structural stability and folding.
In silico studies of fusion proteins based on FimH from UPEC
andMrpH from Proteus mirabilis have revealed that the sequence
order is critical for stability and folding (Habibi et al., 2015a).
Bioinformatics tools were recently used to propose potential
vaccine designs for Helicobacter pylori, enterotoxigenic E. coli,
Brucella, influenza viruses, and UPEC (Nazarian et al., 2012;
Savar et al., 2014; Golshani et al., 2015; Muñoz-Medina et al.,
2015; Habibi et al., 2015b; Mohammad et al., 2016). Additionally,
vaccines have been designed to contain T-cell and B-cell immune
epitopes, and a class II MHC peptide was also identified using
bioinformatics tools (De Groot et al., 2002; De Groot and Moise,
2007). Based on these studies, we evaluated the physicochemical
properties of the amino acid residues, linear epitopes and
peptides binding MHC-II in the primary sequences of the fusion
proteins. Prediction of the physicochemical properties of the
fusion proteins by our “in silico” analysis suggested high amounts
of epitopes and peptides that bound MHC-II; furthermore, there
appeared to be a relationship between the number of epitopes and
the physicochemical properties of the fusion proteins (Sim et al.,
1996; Huang et al., 2016).
The FimH protein contains a mannose-binding lectin domain
between residues 1 and 150 and a pilin domain between residues
159 and 279, with eight amino acids connecting the two domains
(Hung et al., 2002). We identified epitopes and peptides in the
FIGURE 6 | The fusion proteins activate IL-8 release. HTB5 cells were
treated with 10µg/mL of each fusion protein, and IL-8 release into the
supernatant was detected by ELISA. A significant increase (p ≤ 0.037) in IL-8
release was induced by the FCP protein compared to the FC, FimH, CsgA,
and PapG proteins. The FC protein also produced a significant increase (p ≤
0.003) in IL-8 release compared to the FimH, CsgA, and PapG proteins. The
bars represent the mean ± S.D. of three independent experiments. LPS and
LTA (100 ng/mL) were used as controls.
TABLE 5 | Characterization of fusion proteins by DLS.
Sample name T (◦C) Z-Ave (d.nm) PdI
FimH 24.9 132.8 0.276
CsgA 24.9 2.97E + 04 0.948
PapG 25 264.9 0.253
FC 24.9 381.2 0.665
FCP 25 113.8 0.451
PdI ≤ 0.04, monodispersed; PdI ≥ 0.04, polydispersed.
minimal mannose-binding region of FimH (residues 1–25), a
region that has been reported to confer protection against UTIs
caused by UPEC (Thankavel et al., 1997). Similarly, the PapG
protein contains a lectin domain between residues 1 and 198
and a pilin domain between residues 206 and 336 (Sung et al.,
2001). Our data revealed the presence of both epitopes and
peptides of the PapG protein in its Gal(α1-4)Gal-binding region,
between residues 1 and 63 and residues 155 and 173 (Sung
et al., 2001). Moreover, CsgA protein prediction revealed two
epitopes localized in repetitions 4 and 5 that are protein-binding,
functional regions characterized by several beta-turn structures
and exposed domains exhibiting a hydrophilic nature in other
amyloid proteins (Ikai, 1980; Olsén et al., 2002). Interestingly, the
[EAAAK]5 linker used in the fusion proteins does not contain
B-cell epitopes and MHC class II-binding peptides. Moreover,
the fusion proteins exhibited a high percentage of random coil
structure, which have been reported in other models as principal
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FIGURE 7 | Detection of IgG and IgA antibodies in the sera of patients
with UTIs. (A) A significant increase (p ≤ 0.0011) in IgG antibodies in UH-sera
was detected compared to the values for IgG antibodies in HP-sera. (B) IgA
antibodies in UP-sera were significantly increased (p ≤ 0.0001) compared with
IgA antibodies in HP-sera. ELISA was performed in triplicate using three
different samples, and 1µg/mL each protein was used. The points represent
individuals, and the bars represent the median.
components of antigens with flexible regions that allow protein-
protein interactions (Janin and Chothia, 1990; Chen et al., 2007).
3D structure prediction of the fusion proteins confirmed
their stability and correct conformation based on refinement,
energy minimization, and validation analyses. An RMSD value
of 1–2 Å was calculated based on the superimposition of low-
resolution X-ray structures, thus indicating that the fusion
proteins maintained their structures and revealing the mannose-
binding and lectin domains of FimH and PapG in the fusion
proteins. Remarkably, stability and structure are properties that
are related to protein function. In addition, the CsgA protein
has not yet been resolved by crystallography, though circular
dichroism, X-ray diffraction, and NMR data for Curli fibers
suggest the presence of parallel β-sheet structures. 3D models
of CsgA, dimeric (FC and CP), and trimeric proteins proposed
in this study reveal the presence of parallel β-sheet structures
FIGURE 8 | Detection of IgG and IgA antibodies in the urine of patients
with UTIs. (A) A significant increase (p = 0.0011) in IgG antibodies in the urine
of UP patients was detected compared to the values for IgG antibodies in
HP-sera. (B) IgA antibodies in UP-urine were significantly increased
(p = 0.0003) compared with IgA antibodies in HP-sera. ELISA was performed
in triplicate using three different samples, and 1µg/mL each protein was used.
The points represent individuals, and the bars represent the median.
(Shewmaker et al., 2009). Interestingly, the FC and FCP proteins
exhibited high stability and a greater number of epitopes than
the other fusion proteins. FimH, CsgA, and PapG were used as
controls and compared to the fusion proteins. Theoretical data
obtained by bioinformatics tools reduced the risk of failure of the
experimental approaches and optimized resources for generating
on the FC and FCP proteins (Luscombe et al., 2001).
The FimH, CsgA, PapG, FC, and FCP proteins in inclusion
bodies were purified under denaturing conditions. Several
proteins in inclusion bodies have been purified using chaotropic
agents, such as urea and GdnHCl (Wang et al., 2007; Seras-
Franzoso et al., 2015). Purified CsgA protein was visualized
on SDS-PAGE gels only after formic acid treatment, indicating
the formation of amyloid functional aggregates. DLS analysis
revealed a polydispersity index (PdI) of 0.948 and a Z-Average
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FIGURE 9 | Reduction in bacterial adherence in the presence of
polyclonal rabbit antibodies. E. coli strain CFT073 was incubated with 50%
sera from rabbits immunized with the FimH, CsgA, PapG, FC, and FCP
proteins and HTB5 bladder cells (MOI 1:100) for 2 h. Polyclonal rabbit
antibodies favored differing reductions in bacterial adherence (CFU/mL and
percentage) compared with basal adherence of the strain CFT073 and pooled
pre-immune sera. The bars represent the mean ± S.D. of three independent
experiments. **p = 0.0011, ***p = 0.0002, and ****p < 0.0001.
size of 2.97 × 104 nm, which confirmed the aggregation rate of
the CsgA-CsgA interaction. The PdI and Z-Average values of the
FC protein were greater than those of the FCP protein, which
indicates that CsgA linked to FimH and/or PapG promotes low
aggregate formation by the fusion proteins because the domains
of the CsgA proteins were not exposed to interactions with other
CsgA monomers. Therefore, these fusion proteins do not require
pretreatment with formic acid for visualization in SDS-PAGE
gels.
Fusion proteins with bioactivity that depends on separation
(linker), stability, and folding have been described (Chen et al.,
2013). Fimbriae are involved in cytokine release by pathogen-
associated molecular patterns (PAMPs), which are capable of
recognizing pattern recognition receptors (PRRs) such as TLR4
in the mucosa of the urinary tract (Sirard et al., 2006). We
suggest a dependence of the fusion protein-PPR interaction with
regard to the correct structural conformation to induce a pro-
inflammatory response, as described in othermodels (Akira et al.,
2001). A recent study demonstrated that Curli fibers (CsgA) bind
to the TLR2-TLR1 dimer to produce IL-6 release from marrow-
derived macrophages (Rapsinski et al., 2015). Based on these
results, the presence of TLR2 and TLR4 in HTB5 bladder cells
from anaplastic transitional cell carcinoma was described for the
first time in this study (Nayak et al., 1977). In addition, our data
showed that the FimH and PapG proteins could induce release
of IL-6 and IL-8, which bind specifically to TLR4 present on
immune cells and the surface of uroepithelial cells (Frendéus
et al., 2001; Fischer et al., 2006). Compared to the values obtained
for FimH, CsgA, and PapG, the FC and FCP proteins generated in
this study induced significant increases in IL-6 and IL-8 release.
Our data showed that the functionality of the fusion proteins
is involved in the release of high levels of IL-6 and IL-8 when
compared tomonomeric proteins, probably due to the synergistic
signaling of TLR2 and TLR4, an example UPEC strains which
have been linked to the activation of TLR4 and TLR5 pathways,
thereby initiating innate immune responses against UTIs (Cheng
et al., 2016). Conversely, fusion proteins may be considered
PAMPs that are capable of recognizing PRRs as proteins with
adjuvant-type characteristics (Huleatt et al., 2007).
Potential antigens for ideal vaccines should have features
such as surface exposure, expression during infection and
immunogenic properties (Sivick and Mobley, 2010; Brumbaugh
and Mobley, 2012; Mobley and Alteri, 2015). FimH, CsgA,
and PapG proteins are adhesins located on the UPEC surface
(Antão et al., 2009). An immunoproteomic approach has been
used to identify target antigens and viable targets for vaccine
development (Hagan and Mobley, 2007). An immunoproteomic
test based on ELISA analysis of sera and urine from UTI patients
using the fusion proteins was used to determine the antigenicity
and in vivo expression of FimH, PapG, and CsgA. Using the
FimH, CsgA, PapG, FC, and FCP proteins, higher levels of UP-
IgA antibodies were detected in both sera and urine compared
to HP-IgA and UP-IgG antibodies. These data are consistent
with studies using other UPEC proteins (Rene et al., 1982; Rene
and Silverblatt, 1982). Additionally, the antibodies detected in
serum and urine also confirmed FimH, CsgA, and PapG protein
expression in vivo during UTIs caused by UPEC. FC protein
contains exposed epitopes that were recognized by antibodies in
sera and urine, as confirmed by bioinformatics analysis. However,
less robust antigenicity was observed for FCP than FC protein,
likely due to the structural complexity of the former, which
hides potential epitopes. The titration curves for polyclonal rabbit
antibodies against the FCP protein revealed titers > 1:100,000;
however, the anti-CsgA antibodies had titers< 1:1000, indicating
that CsgA may be hidden by 3D folding of the FimH and
PapG proteins (data not shown). A significant reduction in
bacterial adherence by strain CFT073 to HTB5 bladder cells was
observed with the anti-PapG, anti-FC, and anti-FCP polyclonal
rabbit antibodies compared to pre-immune sera and without
antibodies.
In conclusion, recombinant fusion proteins designated FC
and FCP were designed and selected for bioinformatics analysis
and were observed to significantly induce the release of IL-6 and
IL-8. In addition, these proteins exhibited antigenicity based on
the detection of IgG and IgA antibodies in the sera and urine of
UTI patients and the protective functions of antibodies targeting
the fusion proteins in vitro. These data suggest that FC and
FCP proteins are potential biomolecules for generating vaccines
against UTIs caused by UPEC. However, immunogenicity studies
of the FC and FCP proteins are needed to achieve the goal of
developing a vaccine.
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